Home › NDC Lookup › Ingredients › Tiratricol › 87216-0100-01
Emcitate tiratricol 350 ug Tablet, For Suspension — NDC 87216-0100-01 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Emcitate tiratricol 350 ug Tablet, For Suspension — NDC 87216-0100-1 (Billing 87216-0100-01)

by Rare Thyroid Therapeutics International AB · 6 BLISTER PACK in 1 CARTON / 10 TABLET, FOR SUSPENSION in 1 BLISTER PACK
Inner NDC 87216-0100-0 on each blister pack (10 tablet, for suspension) inside this package 11-digit 87216-0100-00

This is a package of Emcitate tiratricol 350 ug Tablet, For Suspension from Rare Thyroid Therapeutics International AB, first listed with the FDA Oct 2026 and currently FDA-listed. It is this product's only package size.

NDC 87216-0100-01
🏷️ FDA NDC (as labeled) 87216-0100-1 billing pads the package segment with a zero
Rx only Brand FDA-listed Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Nov 12, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 87216-0100-1 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
87216 labeler · 0100 product · 1 package
Package marketed since
Oct 26, 2026
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Barcode (UPC)
0387216010017
FDA record last changed
Nov 12, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 87216-0100-1
Product NDC 87216-0100
11-digit billing NDC 87216010001
RxCUI 2755025, 2755031
UNII 29OQ9EU4R1
UPC 0387216010017
Application # NDA220963
SPL Set ID 48d9faab-9c60-4abd-b4b9-97ffa778c944
DEA schedule Non-controlled
Marketing category NDA
Marketing status FDA-listed
FDA listing status Listed (active directory)
Marketing start 2026-10-26
Route ORAL
Dosage form TABLET, FOR SUSPENSION
Substance TIRATRICOL

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 025560
GCN 36641
HICL code 010708
Ingredient (HICL) Tiratricol
HIC1 code P
Therapeutic class — broad (HIC1) Endocrine System
HIC2 code P3
Therapeutic class — intermediate (HIC2) Drugs Affecting Thyroid Function
HIC3 code P3A
Therapeutic class — specific (HIC3) Thyroid Hormones
FDB label name EMCITATE 350 MCG TAB FOR SUSP
FDB brand name Emcitate
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 025560
  • GCN: 36641
  • HICL (First Databank): 010708
  • RxCUI (RxNorm): 2755025
Why two NDCs? The FDA registers this code as 87216-0100-1 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 87216-0100-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name EMCITATE 350 MCG TAB FOR SUSP Ingredient Tiratricol
📗 Our plain-language guide HelloPharmacist
  • It treats peripheral thyrotoxicosis in adults and children with MCT8 deficiency, also called Allan-Herndon-Dudley syndrome. This means too much active thyroid hormone (T3) in the b...
  • If the next dose is more than 4 hours away, give the missed dose as soon as you remember. If the next dose is within 4 hours, skip it and go back to the usual schedule. Never doubl...
  • What happens if I miss a dose of Tiratricol?
  • The tablets are mixed in room-temperature drinking water in an oral syringe and given by mouth or through a feeding tube. Don't swallow, chew or crush them whole. Use the suspensio...
📖 Read our full Tiratricol guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
87216-0100-01 You're viewing this Main listing 6 BLISTER PACK in 1 CARTON / 10 TABLET, FOR SUSPENSION in 1 BLISTER PACK Inner NDC 87216-0100-0 · each blister pack (10 tablet, for suspension) 2026-10-26 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Emcitate 350 ugthis 87216-0100-01 Rare 10 tablets — — FDA listed —
About this product: this is the brand-name version. We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2026
Listed with the FDA since
Oct 2026
📍
2026
Currently FDA-listed
listed with the FDA
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

When could a generic Emcitate arrive?

Our estimate: March 2034 about 7.5 years away

How sure: Probable. More likely than not, but it can still move.

Why then: When a generic maker challenges a patent, FDA must wait up to 30 months before approving it. That wait ends then.

See the full forecast for generic Emcitate →
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color white
ShapeOval
ImprintE
Size10 mm
ScoringScored — splits in 2
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Tiratricol inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII L11K75P92J
    A mineral salt made from calcium and phosphate. It acts as a filler and binder in tablets to add bulk and help hold the medicine together in solid form.
  • UNII EWQ57Q8I5X
    Lactose monohydrate is a natural sugar derived from milk. It serves as a filler and binder in tablets and capsules, helping create the proper size, texture, and consistency of the medicine.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII O8232NY3SJ
    A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.

4 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerRare Thyroid Therapeutics International AB
Application holderRARE THYROID THERAPEUTICS INTERNATIONAL AB
FDA applicationNDA220963 (NDA)
Labeler code87216
First marketedOct 2026
Product typeHuman Prescription Drug
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🚨 Boxed Warning 86 words ▾

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including EMCITATE, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss [see Warnings and Precautions ( 5.2 )]. WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning. Thyroid hormones, including EMCITATE, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss.

( 5.2 )

🎯 Indications and Usage 79 words ▾

1 INDICATIONS AND USAGE EMCITATE is indicated for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-Dudley syndrome). EMCITATE is a thyroid hormone receptor agonist indicated for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-Dudley syndrome). Limitation of Use EMCITATE is not recommended for the treatment of primary hypothyroidism.

Limitation of Use EMCITATE is not recommended for the treatment of primary hypothyroidism.

⏱️ Dosage and Administration ~3 min read ▾

2 DOSAGE AND ADMINISTRATION Individualize dosage based on weight, total T3 levels, and signs and symptoms of thyrotoxicosis. ( 2.1 , 2.2 , 2.3 , 2.4 ) Assess total T3 levels by liquid chromatography tandem mass spectrometry. ( 2.3 ) EMCITATE tablets for oral suspension must be dispersed in room temperature drinking water and administered orally or by enteral feeding tube.

Do not swallow tablets whole. Do not chew or crush tablets. ( 2.7 , 2.8 ) Refer to the Full Prescribing Information for detailed dosage and administration instructions.

( 2 )

2.1Overview EMCITATE dosage is individualized based on weight, total T3 levels, and signs and symptoms of thyrotoxicosis [see Dosage and Administration ( 2.2 , 2.3 , 2.4 ) and Warnings and Precautions ( 5.1 )] . Assess total T3 levels by a liquid chromatography tandem mass spectrometry (LC-MS/MS) method [see Dosage and Administration ( 2.3 )] . EMCITATE tablets for oral suspension must be dispersed in room temperature drinking water and administered orally or by enteral feeding tube.

Do not swallow tablets whole. Do not chew or crush tablets [see Dosage and Administration ( 2.7 , 2.8 )] . Refer to the Instructions for Use (IFU) for detailed instructions on the proper preparation and administration of EMCITATE [see Dosage and Administration ( 2.7 , 2.8 )] .

For pediatric patients less than 8 years of age, consider periodic vision assessment during treatment with EMCITATE to rule out lens abnormalities (e.g., cataract formation) [see Nonclinical Toxicology ( 13.2 )] .

2.2Recommended Dosage Administer the EMCITATE total daily dosage orally or by enteral feeding tube once daily or in two to three divided doses spread throughout the day. The recommended starting dosage for patients weighing: 10 kg or less: 175 mcg/day Greater than 10 kg: 350 mcg/day Titrate dosages based on total T3 levels [see Dosage and Administration ( 2.3 )] . The maximum recommended dosage (mcg/kg) for patients weighing: Less than 10 kg: 100 mcg/kg/day 10 kg to less than 40 kg: 80 mcg/kg/day 40 kg to less than 60 kg: 60 mcg/kg/day 60 kg and above: 50 mcg/kg/day

2.3Dose Titration Measure individual total T3 levels using an LC-MS/MS method. Tiratricol cross-reacts with T3 when assessed by immunoassay, which may cause unreliable test results. An FDA-authorized LC-MS/MS test for the measurement of total T3 is not currently available.

Currently available LC-MS/MS tests used to measure total T3 may vary in accuracy [see Warnings and Precautions ( 5.3 )] . Based on total T3 levels, increase the dosage approximately every two weeks in the following increments for patients weighing: 10 kg or less: 175 mcg/day. Greater than 10 kg: 350 mcg/day.

Increase the dosage until a total T3 level below the midpoint of the normal range for age has been achieved (the maintenance dose) or until the maximum recommended dosage based on weight is achieved [see Dosage and Administration ( 2.2 )] . If total T3 is within the normal range, the dosage may be further adjusted up to the maximum recommended dosage based on the patient's heart rate and blood pressure. Monitor total T3 levels approximately two weeks after these further increases in dosage and assess clinically for new or worsening thyrotoxicosis [ see Dosage and Administration ( 2.4 ), Warnings and Precautions ( 5.1 )].

Once on a stable dose of EMCITATE, reassess total T3 levels once every 6 months and modify the dosage as clinically required.

2.4Dosage Reduction for New or Worsening Thyrotoxicosis If signs or symptoms of thyrotoxicosis either occur for the first time or worsen, and do not resolve within two weeks, reduce the EMCITATE dosage by 175 mcg for patients with a body weight equal to or less than 10 kg or by 350 mcg for patients with a body weight greater than 10 kg [see Warnings and Precautions ( 5.1 )] . Continue to reduce the dosage by these amounts every two weeks, if needed, until the signs or symptoms of thyrotoxicosis have resolved. Following the resolution of thyrotoxic… [Excerpted — this section continues on DailyMed.]

💊 Dosage Forms and Strengths 44 words ▾

3 DOSAGE FORMS AND STRENGTHS Tablets for oral suspension: 350 mcg. White oblong tablet with functional scoring on both sides. Debossed with “E” on one side of the tablet, mirrored on both halves. Tablets for oral suspension: 350 mcg (functional scoring) ( 3 )

⛔ Contraindications 23 words ▾

4 CONTRAINDICATIONS EMCITATE is contraindicated in patients with primary hyperthyroidism [see Warnings and Precautions ( 5.1 )] . Primary hyperthyroidism. ( 4 )

⚠️ Warnings and Cautions ~1 min read ▾

5 WARNINGS AND PRECAUTIONS Thyrotoxicosis : Signs and symptoms of thyrotoxicosis (e.g., increased heart rate, elevated blood pressure, diarrhea, hyperhidrosis, irritability, insomnia, nightmares) have occurred with EMCITATE during treatment initiation and dose titration. Monitor and adjust the EMCITATE dose as indicated. ( 5.1 ) Laboratory Test Interference for T3 Measurement : Tiratricol can cross-react with immunoassays for T3 leading to unreliable T3 results and cause an overestimation of T3.

( 5.3 )

5.1New Onset or Worsening of Thyrotoxicosis Signs and symptoms of thyrotoxicosis, such as increased heart rate, elevated blood pressure, diarrhea, hyperhidrosis, irritability, insomnia, and nightmares, have occurred in patients receiving EMCITATE [see Adverse Drug Reactions ( 6.1 )] . These symptoms may occur if the EMCITATE dose is further increased despite T3 normalization, due to a drug-induced thyromimetic effect [see Dosage and Administration ( 2 )] . Signs and symptoms of thyrotoxicosis may also occur during the dose titration period due to a combined thyromimetic effect from endogenous T3 levels that have not yet declined and EMCITATE.

If signs and symptoms of thyrotoxicosis occur despite T3 level normalization, decrease the EMCITATE dose according to the dose titration schedule [see Dosage and Administration ( 2.4 )] . If signs and symptoms of thyrotoxicosis do not resolve within 2 weeks after dose down-titration, the dose should be further reduced [see Dosage and Administration ( 2.3 , 2.4 )] .

5.2Not for Treatment of Obesity or Weight Loss EMCITATE should not be taken for weight reduction as it may cause symptoms of thyrotoxicosis that could be serious or life-threatening.

5.3Laboratory Test Interference for T3 Measurement Tiratricol can cross-react with T3 immunoassays leading to unreliable T3 results. When present, such cross-reactivity causes an overestimation of T3. Cross-reactivity of tiratricol is not expected to impact measurement of T3 by LC-MS/MS. An FDA-authorized LC-MS/MS test for the measurement of total T3 is not currently available.

🤒 Adverse Reactions ~1 min read ▾

6 ADVERSE REACTIONS Most common adverse reactions (≥ 5%): diarrhea, vomiting, rash, and hyperhidrosis. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Egetis Therapeutics US Inc. at 1-844-4EGETIS (1-844-434-3847) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of EMCITATE in patients with MCT8 deficiency was evaluated in two studies. Study 1 (NCT05579327) was a 3-period, multicenter study with an up to 16-week, open-label, titration period followed by a 30-day randomized double-blind, placebo-controlled withdrawal period, then a 6-week open-label treatment period.

Study 1 enrolled 20 male patients with MCT8 deficiency. Study 2 (NCT02060474) was an open-label, single-arm, multicenter study of 12 months duration that enrolled 46 male patients with MCT8 deficiency [see Clinical Studies ( 14 )] . Adverse reactions reported in ≥ 5% of patients treated with EMCITATE are summarized in Table 1 .

Table 1. Adverse Drug Reactions in ≥ 5% of Patients in Study 1 and Study 2 Adverse Reactions Study 1 EMCITATE N = 20 n (%) Study 2 EMCITATE N = 46 n (%) Diarrhea 0 6 (13) Vomiting 2 (10) 5 (11) Rash 2 (10) 4 (9) Hyperhidrosis 1 (5) 3 (7) Signs and symptoms of thyrotoxicosis In Study 2, transient increases in heart rate (≥ 10 bpm) and systolic blood pressure (≥ 5 mmHg) were observed in 35% and 26% of participants, respectively, during the titration period. In addition, 30% of participants experienced at least one adverse reaction potentially related to thyrotoxicosis during the trial (diarrhea, hyperhidrosis, irritability, insomnia, nightmares), with most of these adverse reactions occurring during the titration period [see Warnings and Precautions ( 5.1 )].

🔄 Drug Interactions ~3 min read ▾

7 DRUG INTERACTIONS Not recommended with other thyroid medications ( 7.1 ) See full prescribing information for drugs that may interact with EMCITATE and alter the therapeutic response ( 7.2 - 7.4 ).

7.1Not Recommended with Other Thyroid Medications Taking EMCITATE in combination with thyromimetic products or products used to treat thyroid conditions (e.g., levothyroxine, propylthiouracil, and carbimazole) may increase the risk of thyrotoxicosis or hypothyroidism and should be avoided.

7.2Drugs that may Affect Thyroid Hormone Pharmacokinetics Many drugs can exert effects on thyroid hormone pharmacokinetics and may alter the therapeutic response. No clinical drug interaction studies have been conducted with EMCITATE. Tables 2 to 4 provide a summary of expected potential clinically significant drug interactions with EMCITATE.

Table 2. Drugs that May Affect Tiratricol Absorption Potential impact: Concurrent use may affect the efficacy of EMCITATE by binding and altering absorption. Drug or Drug Class Effect Clinical Recommendation Bile acid sequestrants Ion exchange resins Iron and calcium supplements Bile acid sequestrants and ion exchange resins decrease thyroid hormone exposure by binding and delaying or preventing absorption.

Concurrent use may reduce the efficacy of EMCITATE. Iron and calcium may interfere with the absorption of tiratricol. Avoid concomitant use of bile acid sequestrants and ion exchange resins with EMCITATE.

Iron and calcium supplements can reduce tiratricol exposure. If concomitant use of iron or calcium supplements is necessary, administer iron or calcium supplements consistently at the same time each day relative to EMCITATE dosing. Proton pump inhibitors (PPIs) Changes in gastric pH associated with PPI therapy may increase the absorption of tiratricol.

Serum concentrations of T3 should be monitored and dose adjustments of EMCITATE considered when initiating, modifying or discontinuing PPI treatment. Table 3. Drugs that May Alter Plasma Binding of Triiodothyronine (T3) Potential Impact: Changes in serum plasma protein levels can alter concentrations of thyroid hormones (total T3 levels).

Drug or Drug Class Effect Clinical Recommendation Oral estrogen containing products These drugs may increase serum thyroxine-binding globulin (TBG) concentration and increase total T3 serum levels. Monitor clinical symptoms and evaluate free T3 levels. Anabolic steroids and glucocorticoids These drugs may decrease serum TBG concentration and decrease total T3 serum levels.

Salicylates (> 2 g/day) Salicylates inhibit binding of T3 to TBG and transthyretin and may inhibit binding of tiratricol to transthyretin. Table 4. Drugs that May Alter Hepatic Metabolism of Tiratricol and Thyroid Hormones Potential impact: Stimulation of hepatic drug-metabolizing enzyme activity may cause increased hepatic degradation of tiratricol and thyroid hormones, resulting in an increased EMCITATE dose requirement.

Drug or Drug Class Effect Clinical Recommendation Drugs that may increase hepatic metabolism of tiratricol Administration of drugs that increase hepatic drug-metabolizing enzyme activity may increase the hepatic degradation of thyroid hormones and tiratricol. Serum concentrations of thyroid hormones should be monitored and dose adjustments of EMCITATE considered when initiating, titrating or discontinuing treatment with enzyme inducing agents.

7.3Oral Anticoagulants EMCITATE may increase the response to oral anticoagulant therapy, which may increase the risk of hemorrhage. Therefore, a reduction in the dose of anticoagulant may be warranted if administered concomitantly with EMCITATE. Closely monitor coagulation tests to permit appropriate and timely dosage adjustments of the anticoagulant.

7.4Psychostimulants Administration of psychostimulants (e.g., caffeine, norepinephrine–dopamine reuptake inhibitors (NDRIs), and amphetamines) in combination with high doses of EMCITATE may lead to increased heart rate and blood pressure. Conc… [Excerpted — this section continues on DailyMed.]

👥 Use in Specific Populations ~1 min read ▾

8 USE IN SPECIFIC POPULATIONS

8.1Pregnancy There are no available data on the use of tiratricol for the treatment of MCT8 deficiency during pregnancy to inform a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with tiratricol. The background risk of major birth defects and miscarriage for the indicated population is unknown.

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

8.2Lactation There are no data regarding the presence of tiratricol in human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EMCITATE and any potential adverse effects on the breastfed infant from EMCITATE or the underlying maternal condition.

8.4Pediatric Use The safety and effectiveness of EMCITATE for the treatment of peripheral thyrotoxicosis have been established in pediatric patients with MCT8 deficiency. Use of EMCITATE in pediatric patients is supported by a single-arm trial and a double-blind, placebo-controlled, randomized withdrawal trial that included pediatric patients with MCT8 deficiency ages 10 months to less than 2 years (n=5), ages 2 years to less than 12 years (n=38), and ages 12 years to less than 17 years (n=12) [see Clinical Studies ( 14 )] .

8.5Geriatric Use MCT8 deficiency is largely a disease of children and young adults; therefore, there are insufficient data on the use of EMCITATE in patients aged 65 years and older to determine whether they respond differently from younger patients.

🤰 Pregnancy 103 words ▾

8.1Pregnancy There are no available data on the use of tiratricol for the treatment of MCT8 deficiency during pregnancy to inform a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with tiratricol. The background risk of major birth defects and miscarriage for the indicated population is unknown.

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

🧒 Pediatric Use 85 words ▾

8.4Pediatric Use The safety and effectiveness of EMCITATE for the treatment of peripheral thyrotoxicosis have been established in pediatric patients with MCT8 deficiency. Use of EMCITATE in pediatric patients is supported by a single-arm trial and a double-blind, placebo-controlled, randomized withdrawal trial that included pediatric patients with MCT8 deficiency ages 10 months to less than 2 years (n=5), ages 2 years to less than 12 years (n=38), and ages 12 years to less than 17 years (n=12) [see Clinical Studies ( 14 )] .

🧓 Geriatric Use 40 words ▾

8.5Geriatric Use MCT8 deficiency is largely a disease of children and young adults; therefore, there are insufficient data on the use of EMCITATE in patients aged 65 years and older to determine whether they respond differently from younger patients.

🧬 Clinical Pharmacology ~3 min read ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action Tiratricol is a thyroid hormone receptor (THR) agonist which, unlike triiodothyronine (T3) and thyroxine (T4), can enter cells independent of the transmembrane transporter protein MCT8. In patients with MCT8 deficiency, X-linked loss-of-function mutations in the SLC16A2 gene encoding MCT8 impair T3 entry into target tissues. This results in insufficient T3 activity in the brain concurrent with persistent peripheral thyrotoxicosis from accumulation of circulating T3.

Intracellular tiratricol activity at THR-β, independent of MCT8-mediated membrane transport, can modulate hypothalamic-pituitary-thyroid axis signaling and reduce circulating T3 in patients with MCT8 deficiency.

12.2Pharmacodynamics Tiratricol reduces elevated T3 concentrations in patients with MCT8 deficiency in a concentration-dependent manner, with greater T3-lowering effect at higher tiratricol exposures; however, this effect plateaus at or above mean tiratricol concentrations of approximately 746 ng/dL in patients 5 years and older. Following discontinuation of EMCITATE, total T3 concentrations increased toward pretreatment levels within one week. Cardiac Electrophysiology There is insufficient information to characterize the effect of tiratricol on the QTc interval.

12.3Pharmacokinetics The area under the plasma concentration-time curve (AUC) and maximal plasma concentration (Cmax) of tiratricol increased dose proportionally over the dose range studied (175 mcg to 1050 mcg) after oral administration. Administration of EMCITATE via an enteral tube compared to standard oral administration did not affect tiratricol pharmacokinetics. Absorption The absorption of tiratricol is rapid with a median time to maximum plasma concentration (T max ) of 0.5 hours (range 0.25 to 1 hour).

Effect of Food Administration of EMCITATE in healthy volunteers at doses of 175 mcg and 1050 mcg with a high-fat high-calorie meal (956 kcal energy, 35 g protein, 65 g carbohydrate and 61 g fat (with 57% energy from fat)) resulted in a delayed T max (1 hour), reduced C max (67%-70%), and unchanged AUC, compared to fasted conditions. These changes are not clinically significant [see Dosage and Administration ( 2.8 )] . Distribution Tiratricol plasma protein binding is 99%.

The apparent volume of distribution is 364 L for a 70 kg patient and 130 L for a 25 kg patient. Elimination The apparent clearance of tiratricol is 21 L/hr for a 70 kg patient and 10 L/hr for a 25 kg patient. The steady state half-life is approximately 12 hours for a 70 kg patient and 9.4 hours for a 25 kg patient.

Metabolism Tiratricol is metabolized by stepwise deiodination, sulfation and glucuronidation, mainly in the liver. Excretion Tiratricol and its metabolites are predominantly eliminated in urine as inorganic iodine and in bile. Specific Populations No clinical studies have been performed in subjects with renal and hepatic impairment.

Pediatric Patients Pediatric patients (5 to 16 years of age) with a lower body weight had a lower clearance and volume of distribution as compared to adult patients. Drug Interaction Studies No clinical drug-drug interaction studies have been performed with tiratricol. In vitro studies CYP450 Enzymes: Tiratricol is unlikely to inhibit or induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 at clinically relevant doses.

UGT Enzymes: Tiratricol is unlikely to inhibit UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, UGT2B15 and UGT2B17 at clinically relevant doses. Transporters: Tiratricol is not a substrate for P-gp, BCRP, OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1 or MATE2-K. Tiratricol is unlikely to inhibit BCRP, OAT1, OAT3, OATP1B1 transporters at clinically relevant doses.

🧬 Mechanism of Action 92 words ▾

12.1Mechanism of Action Tiratricol is a thyroid hormone receptor (THR) agonist which, unlike triiodothyronine (T3) and thyroxine (T4), can enter cells independent of the transmembrane transporter protein MCT8. In patients with MCT8 deficiency, X-linked loss-of-function mutations in the SLC16A2 gene encoding MCT8 impair T3 entry into target tissues. This results in insufficient T3 activity in the brain concurrent with persistent peripheral thyrotoxicosis from accumulation of circulating T3.

Intracellular tiratricol activity at THR-β, independent of MCT8-mediated membrane transport, can modulate hypothalamic-pituitary-thyroid axis signaling and reduce circulating T3 in patients with MCT8 deficiency.

📦 How Supplied / Storage and Handling 92 words ▾

16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied EMCITATE (tiratricol) tablets for oral suspension, 350 mcg, are white, oblong tablets (size: 10 mm long, 5 mm wide) with functional score lines on both sides of the tablet and debossed with “E” on one side of the tablet, mirrored on both halves. They are supplied as follows: NDC 87216-0100-1: PVC/Aluminum blisters, 60 tablets for oral suspension. Each outer carton contains 6 blister cards of 10 tablets each.

Storage and Handling Store refrigerated at 2°C to 8°C (36°F to 46°F), and keep protected from light.

📦 Storage and Handling 17 words ▾

Storage and Handling Store refrigerated at 2°C to 8°C (36°F to 46°F), and keep protected from light.

📋 Description 118 words ▾

11 DESCRIPTION EMCITATE tablets for oral suspension contain tiratricol, a thyroid hormone receptor agonist. The chemical name for tiratricol is 2-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]acetic acid. The molecular formula of tiratricol is C 14 H 9 I 3 O 4 , its molecular weight is 621.93 g/mol and its chemical structure is depicted below.

Tiratricol is a white to off-white solid powder, with a pH-dependent solubility in water. EMCITATE tablets for oral suspension are supplied as 350 mcg strength to be administered as a suspension orally or via an enteral feeding tube directly into the stomach. Each tablet contains tiratricol as the active ingredient and the following inactive ingredients: anhydrous dibasic calcium phosphate, corn starch, lactose monohydrate, and magnesium stearate.

Chemical Structure

💬 Information for Patients ~2 min read ▾

17 PATIENT COUNSELING INFORMATION Advise patients and caregivers to read the FDA-approved Instructions for Use. Dosing Advise patients and caregivers to read and carefully follow the instructions for dose titration and adjustment [see Dosage and Administration ( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 )]. If a dose is missed and there are more than 4 hours to the next scheduled dose, inform patients and caregivers to take the missed dose as soon as possible.

If a dose is missed and the next dose is scheduled within 4 hours, inform patients and caregivers to skip the dose and take the next dose according to the regular schedule. Doses should not be doubled. Inform patients and caregivers to administer a new dose if a patient vomits within 30 minutes after administration and to contact their healthcare provider if vomiting recurs [see Dosage and Administration ( 2.5 )] .

Preparation and Administration Advise patients and caregivers that tablets should not be swallowed whole, chewed, crushed or mixed with any other vehicle than water. Advise patients and caregivers to read and carefully follow the FDA-approved Instructions for Use for proper preparation and administration of EMCITATE [see Instructions for Use] . Inform patients and/or caregivers not to stop taking EMCITATE abruptly or without first checking with their healthcare providers as there will be a need for gradual dose reductions to decrease the risk of thyrotoxic symptoms and signs.

Drug Interactions Inform patients and caregivers that EMCITATE may interact with many drugs [see Contraindications ( 4 ), Warnings and Precautions ( 5.1 ), Drug Interactions ( 7 )] . Advise patients and their caregivers to report the patient's use of all prescription and nonprescription medications, including nutritional supplements and vitamins. Signs and Symptoms of Thyrotoxicosis Advise patients to report signs and symptoms of thyrotoxicosis (such as hyperhidrosis, irritability, insomnia, nightmares, increases in heart rate and elevations in systolic blood pressure, or diarrhea) that occur for the first time or worsen during treatment, and inform them that their dose may be adjusted until signs and symptoms resolve [see Dosage and Administration ( 2.4 )].

Manufactured for: Rare Thyroid Therapeutics International AB Klara Norra Kyrkogata 26 Stockholm, Sweden 111 22 Distributed by Egetis Therapeutics US Inc., Cambridge, MA 02142, USA. EMCITATE ® is a registered trademark of Rare Thyroid Therapeutics International AB

🧬 Pharmacokinetics ~2 min read ▾

12.3Pharmacokinetics The area under the plasma concentration-time curve (AUC) and maximal plasma concentration (Cmax) of tiratricol increased dose proportionally over the dose range studied (175 mcg to 1050 mcg) after oral administration. Administration of EMCITATE via an enteral tube compared to standard oral administration did not affect tiratricol pharmacokinetics. Absorption The absorption of tiratricol is rapid with a median time to maximum plasma concentration (T max ) of 0.5 hours (range 0.25 to 1 hour).

Effect of Food Administration of EMCITATE in healthy volunteers at doses of 175 mcg and 1050 mcg with a high-fat high-calorie meal (956 kcal energy, 35 g protein, 65 g carbohydrate and 61 g fat (with 57% energy from fat)) resulted in a delayed T max (1 hour), reduced C max (67%-70%), and unchanged AUC, compared to fasted conditions. These changes are not clinically significant [see Dosage and Administration ( 2.8 )] . Distribution Tiratricol plasma protein binding is 99%.

The apparent volume of distribution is 364 L for a 70 kg patient and 130 L for a 25 kg patient. Elimination The apparent clearance of tiratricol is 21 L/hr for a 70 kg patient and 10 L/hr for a 25 kg patient. The steady state half-life is approximately 12 hours for a 70 kg patient and 9.4 hours for a 25 kg patient.

Metabolism Tiratricol is metabolized by stepwise deiodination, sulfation and glucuronidation, mainly in the liver. Excretion Tiratricol and its metabolites are predominantly eliminated in urine as inorganic iodine and in bile. Specific Populations No clinical studies have been performed in subjects with renal and hepatic impairment.

Pediatric Patients Pediatric patients (5 to 16 years of age) with a lower body weight had a lower clearance and volume of distribution as compared to adult patients. Drug Interaction Studies No clinical drug-drug interaction studies have been performed with tiratricol. In vitro studies CYP450 Enzymes: Tiratricol is unlikely to inhibit or induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 at clinically relevant doses.

UGT Enzymes: Tiratricol is unlikely to inhibit UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, UGT2B15 and UGT2B17 at clinically relevant doses. Transporters: Tiratricol is not a substrate for P-gp, BCRP, OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1 or MATE2-K. Tiratricol is unlikely to inhibit BCRP, OAT1, OAT3, OATP1B1 transporters at clinically relevant doses.

🧬 Pharmacodynamics 74 words ▾

12.2Pharmacodynamics Tiratricol reduces elevated T3 concentrations in patients with MCT8 deficiency in a concentration-dependent manner, with greater T3-lowering effect at higher tiratricol exposures; however, this effect plateaus at or above mean tiratricol concentrations of approximately 746 ng/dL in patients 5 years and older. Following discontinuation of EMCITATE, total T3 concentrations increased toward pretreatment levels within one week. Cardiac Electrophysiology There is insufficient information to characterize the effect of tiratricol on the QTc interval.

🔬 Clinical Studies ~3 min read ▾

14 CLINICAL STUDIES The efficacy of EMCITATE in patients with MCT8 deficiency was evaluated in two studies; Study 1 (NCT05579327) and Study 2 (NCT02060474). Study 1 The efficacy of EMCITATE in patients with MCT8 deficiency was evaluated in an international, multicenter study (Study 1; NCT05579327) that consisted of three study periods as follows: Screening Period (Run-in/Titration period): 6-week run-in period for participants already treated with EMCITATE (Cohort A) and a 16-week dose-titration period for participants newly started on EMCITATE (Cohort B).

Randomized Treatment Period (RTP): 30-day double-blind, placebo-controlled, randomized withdrawal period, which provided data for the primary efficacy endpoints. Follow-up Period: 6-week open-label treatment period. Screening Period: Twenty participants with MCT8 deficiency were enrolled during the Screening Period: 10 participants in Cohort A, who were already receiving EMCITATE treatment, and 10 participants in Cohort B, who were started on EMCITATE 350 mcg daily.

The EMCITATE dose was titrated by 350 mcg daily every 2 weeks based on serum total T3 to achieve the stable dose criterion. The stable dose criterion was defined as at least 4 weeks of treatment with a fixed daily dose of EMCITATE and at least 2 consecutive serum total T3 results within the target range (between 80% of the lower limit of normal and no higher than the 75 th percentile of the normal range). The mean duration of treatment with EMCITATE during this period was 86 days in Cohort A and 77 days in Cohort B.

The median age of the 20 participants enrolled in the study was 11 years, ranging from 5 to 31 years. All subjects were male. There were 65% White, 15% Black or African Americans, 5% Asian, 5% American Indian or Alaska Native and 10% other races.

Randomized Treatment Period: Fifteen participants (8 participants from Cohort A and 7 participants from Cohort B) achieved the stable dose criterion and were randomized (1:1) to receive placebo or continue EMCITATE treatment for 30 days or until the rescue criterion, defined as the serum total T3 above the upper limit of normal (ULN), was met. Serum total T3 was measured weekly during this period. If the rescue criterion was met, the subject stopped the blinded study treatment and re-initiated EMCITATE at the pre-randomization dose.

Follow-up Period: After completion of the RTP, 14 participants entered a 6-week follow-up period and received EMCITATE at the stable maintenance dose received prior to randomization. Efficacy Assessment and Results The two primary efficacy endpoints were: 1) Rate of change from baseline in serum total T3 during the 30-day Randomized Treatment Period; 2) Proportion of participants who met the rescue criterion during the 30-day Randomized Treatment Period. The results for primary efficacy endpoint 1 are presented in Table 5 .

Table 5. Total T3 Rate of Change During Randomized Treatment Period (Full Analysis Set) Note: Estimates from random effects model Abbreviations: CI = confidence interval; T3 = triiodothyronine Treatment N T3 rate of change [95% CI] Ratio of T3 rate of change Placebo/Tiratricol [95% CI] Placebo 8 1.6 [1.2; 2.1] 1.5 [1.0; 2.2] (p-value=0.034) Tiratricol 7 1.1 [0.8; 1.3] The mean (SD) change from baseline to the end of the Randomized Treatment Period in total T3 levels was 64.6 (12.7) ng/dL from a baseline of 109.1 ng/dL in the placebo arm and -0.2 (12.5) ng/dL from a baseline of 100.5 ng/dL in the tiratricol arm.

The treatment difference (95% CI) in total T3 change from baseline at the end of randomized treatment period was 64.8 ng/dL (44.7, 84.8) for placebo versus tiratricol arm. The results for primary efficacy endpoint 2 (proportion of participants meeting the rescue criterion during the Randomized Treatment Period) are provided in Table 6 . Table 6.

Proportion of Subjects Who Met the Rescue Criterion (Serum Total T3 > ULN) During the 30-day Double-Blind Randomized Treatment Period (Full Analysis Set) Note:*… [Excerpted — this section continues on DailyMed.]

🧪 Nonclinical Toxicology 169 words ▾

13 NONCLINICAL TOXICOLOGY

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Tiratricol was not carcinogenic in Tg-RasH2 mouse carcinogenicity studies up to the highest tolerable dose tested of 15 mg/kg/day. Mutagenesis Tiratricol was not genotoxic in a bacterial reverse mutation assay, an in vitro micronucleus assay in human lymphoblastoid cells, and in an in vivo rat bone marrow micronucleus assay. Impairment of Fertility Dedicated fertility studies have not been conducted with tiratricol.

13.2Ophthalmologic Findings Beagle dogs treated orally for 13 weeks with 0, 0.15, 0.5, or 5 mg/kg/day tiratricol had lens opacities and lens fiber degeneration in all animals treated at the highest dose (approximately 24-fold clinical exposures based on AUC estimates). There were no adverse ophthalmologic findings in dogs treated with ≤0.5 mg/kg/day tiratricol (approximately 3- to 7-fold higher than clinical exposures based on AUC and C max , respectively). The risk of ocular toxicity from tiratricol use in humans is unknown, but is considered low based on the absence of findings in dogs at clinically relevant exposures.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 68 words ▾

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Tiratricol was not carcinogenic in Tg-RasH2 mouse carcinogenicity studies up to the highest tolerable dose tested of 15 mg/kg/day. Mutagenesis Tiratricol was not genotoxic in a bacterial reverse mutation assay, an in vitro micronucleus assay in human lymphoblastoid cells, and in an in vivo rat bone marrow micronucleus assay. Impairment of Fertility Dedicated fertility studies have not been conducted with tiratricol.

📄 Patient Package Insert ~3 min read ▾

INSTRUCTIONS FOR USE EMCITATE ® (EM-si-tayt) (tiratricol) tablets for oral suspension This Instructions for Use contains information on how to give EMCITATE tablets for oral mixture (suspension). Read this Instructions for Use before you start giving EMCITATE and each time you get a refill. There may be new information.

This information does not take the place of talking to your healthcare provider about the medical condition or treatment of your child or the person for whom you are caring. Important Information You Need to Know Before Giving EMCITATE Only give EMCITATE as a suspension by mouth or through a feeding tube, as directed by your healthcare provider. Do not swallow whole, chew or crush tablet.

Your healthcare provider will tell you the number of tablets to give for each dose and how often to give the medication throughout the day. Give exactly as your healthcare provider tells you. Do not give less EMCITATE, immediately stop giving EMCITATE or give more EMCITATE than prescribed by your healthcare provider.

Prepare the dose only when you are ready to give it. Prepare no more than 3 tablets in the syringe at a time. Mix EMCITATE in room temperature drinking water before giving . the tablet will not fully dissolve. the suspension will look white and cloudy with small particles , this is normal.

Do not mix EMCITATE with any foods, liquids or feeding formulas other than room temperature drinking water. EMCITATE can be given before or after food. Throw away (dispose of) any unused suspension 30 minutes after preparing it.

See “ Disposing of EMCITATE Tablets or Oral Suspension ”. If you are not sure how to prepare or give a dose, contact your healthcare provider or pharmacist. Missed dose or vomiting: If you miss a dose: If there are more than 4 hours before the next dose, give the missed dose as soon as possible.

If there are less than 4 hours before the next dose, skip the missed dose and continue with the regular schedule. Do not double the dose. If vomiting happens within 30 minutes of giving a dose, give the dose again.

If vomiting happens a second time, do not give another dose. Contact your healthcare provider. Supplies You Will Need Supplies included: Prescribed number of EMCITATE tablets for each dose Supplies not included: A clean drinking glass with room temperature drinking water A 10 to 12 mL oral syringe with a cap (provided by your healthcare provider or pharmacist) An enteral feeding tube and matching 10 to 12 mL syringe for enteral feeding (if needed) A pill cutter (if needed) Preparing a Dose of EMCITATE Suspension If more than 3 tablets are needed for your single dose, divide the dose into multiple separate preparations not to exceed 3 tablets per preparation and repeat Steps 1 through 5 for each preparation.

Step 1: Wash and dry your hands. Step 2: Fill about half a clean glass with room temperature drinking water (see Figure A ). Only use room temperature drinking water to prepare the dose.

Figure A Step 3: Remove the number of tablets needed for your dose from the blister pack. If your single dose is more than 3 tablets, divide it into multiple separate preparations to give right away. Tear along the dotted line to separate each pill (blister) unit (see Figure B ).

Figure B Peel back the paper layer starting from the corner with the arrow (see Figure C ). Figure C Push the tablet out through the foil (see Figure D ). Figure D If the prescribed dose requires using a half tablet: break the tablet in half along the line in the middle (score).

You can do this by hand (see Figure E ) or with a pill cutter (see Figure F ). put the unused half tablet back into the original blister pack and outer carton (or the light-protective packaging from the pharmacy). See ” Storing EMCITATE ”. Figure E Figure F Step 4: Load the tablets into the oral or enteral syringe.

Remove the cap from the tip of the syringe (see Figure G ). Figure G Pull out the plunger from the back of the syringe (see Figure H ). Figure H Put the… [Excerpted — this section continues on DailyMed.]

📄 Package Label / Principal Display Panel 91 words ▾

Principal Display Panel - 350 mcg Carton Label NDC 87216-0100-1 Rx only Emcitate ® (tiratricol) tablets for oral suspension 350 mcg per tablet 60 tablets for oral suspension Carton contains 6 individual blister cards of 10 tablets for oral suspension. Tablets must be dispersed in water Tablets must not be swallowed whole, chewed or crushed. Figure

Principal Display Panel - 350 mcg Blister Pack Label Emcitate ® (tiratricol) tablets for oral suspension 350 mcg per tablet Store refrigerated at 2°C to 8°C (36°F to 46°F) Rare Thyroid Therapeutics NDC 87216-0100-0 Figure

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Rare Thyroid Therapeutics International AB. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Rare Thyroid Therapeutics International AB is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.